As of 2024-12-13, the EV/EBITDA ratio of Kymera Therapeutics Inc (KYMR) is -13.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KYMR's latest enterprise value is 2,623.72 mil USD. KYMR's TTM EBITDA according to its financial statements is -189.02 mil USD. Dividing these 2 quantities gives us the above KYMR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.0x | 16.0x |
| Forward P/E multiples | 15.4x - 21.2x | 15.7x |
| Fair Price | (43.28) - (47.83) | (44.59) |
| Upside | -202.6% - -213.4% | -205.7% |
| Date | EV/EBITDA |
| 2024-12-11 | -14.86 |
| 2024-12-10 | -14.87 |
| 2024-12-09 | -14.39 |
| 2024-12-06 | -15.42 |
| 2024-12-05 | -14.54 |
| 2024-12-04 | -15.20 |
| 2024-12-03 | -15.51 |
| 2024-12-02 | -15.79 |
| 2024-11-29 | -15.48 |
| 2024-11-27 | -15.49 |
| 2024-11-26 | -15.19 |
| 2024-11-25 | -15.54 |
| 2024-11-22 | -14.84 |
| 2024-11-21 | -14.34 |
| 2024-11-20 | -14.53 |
| 2024-11-19 | -14.11 |
| 2024-11-18 | -13.96 |
| 2024-11-15 | -13.81 |
| 2024-11-14 | -15.17 |
| 2024-11-13 | -16.09 |
| 2024-11-12 | -16.56 |
| 2024-11-11 | -17.19 |
| 2024-11-08 | -16.89 |
| 2024-11-07 | -16.52 |
| 2024-11-06 | -16.39 |
| 2024-11-05 | -15.77 |
| 2024-11-04 | -15.56 |
| 2024-11-01 | -15.35 |
| 2024-10-31 | -15.25 |
| 2024-10-30 | -15.77 |
| 2024-10-29 | -16.05 |
| 2024-10-28 | -16.25 |
| 2024-10-25 | -15.88 |
| 2024-10-24 | -16.13 |
| 2024-10-23 | -16.14 |
| 2024-10-22 | -16.01 |
| 2024-10-21 | -15.39 |
| 2024-10-18 | -15.33 |
| 2024-10-17 | -15.28 |
| 2024-10-16 | -16.23 |
| 2024-10-15 | -14.78 |
| 2024-10-14 | -15.21 |
| 2024-10-11 | -14.86 |
| 2024-10-10 | -14.25 |
| 2024-10-09 | -14.28 |
| 2024-10-08 | -14.18 |
| 2024-10-07 | -13.89 |
| 2024-10-04 | -14.19 |
| 2024-10-03 | -14.31 |
| 2024-10-02 | -14.85 |